By staff writers

March 16, 2018 -- Japan has adopted new restrictions on the use of linear gadolinium-based contrast agents (GBCAs), according to an editorial written by Dr. Tomonori Kanda of Kobe University and published online on March 16 in Magnetic Resonance in Medical Sciences.

The current Japanese market allows for use of both linear and macrocyclic GBCAs. But in November 2017, package inserts for GBCAs in Japan were revised to include the following two new recommendations:

  • Physicians should consider restricting GBCA use to clinical circumstances in which the information provided by the contrast is necessary.
  • Macrocyclic GBCAs are the primary choice; linear GBCAs should be used when macrocyclic agents are not indicated due to patient history of adverse effects (with the exception of linear agent gadoxetic acid).

These new recommendations mean that gadodiamide and gadopentetate dimeglumine (linear agents) can be used only in patients who had adverse effects from macrocyclic GBCAs, Kanda wrote.

"Although the risk of adverse effects due to gadolinium deposition in the brain is not proven, the use of linear gadolinium has been restricted in this revised package insert in view of the risk of possible adverse events in the future," he concluded.

No gadolinium needed for follow-up MRI inner ear scans
VIENNA - Once an initial MRI scan with gadolinium-based contrast has confirmed an intralabyrinthine schwannoma, the contrast agent shouldn't be needed...
Japan requires changes in GBCA labeling information
Japan's Ministry of Health, Labor, and Welfare is following suit with regulatory agencies in the U.S. and Europe in asking four makers of gadolinium-based...
Norris lawsuit puts personal face on gadolinium debate
The controversy over retained gadolinium from MRI just got personal. The lawsuit filed November 1 by action film star Chuck Norris and his wife Gena against...
Evidence mounts: Use macrocyclic GBCAs in pediatric MRI
Could macrocyclic gadolinium-based contrast agents (GBCAs) become the standard MRI protocol for pediatric patients? German researchers think so, after...
FDA panel to tackle questions on gadolinium retention
The baffling issue of gadolinium retention in patients receiving gadolinium-based contrast agents for MRI scans will be front and center before a committee...

Copyright © 2018

Last Updated rm 3/16/2018 10:22:55 AM